Given that anti‐CXCL8[54] and anti‐NET therapies[55] are currently being evaluated in clinical trials for the treatment of solid tumors, our study also proposes SKAP1 as a novel biomarker to identify patients with colon cancer who may benefit from these therapies. Here, SKAP1 is linked to malignant colon neoplasm.